Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shiwei Longdanhua capsule versus Feilike capsule for acute exacerbation of chronic bronchitis
ChiCTR2200066665Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Nov 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shiwei Longdanhua in chronic bronchitis (CB) (2 arms), sponsored by Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints: Curative effect of TCM syndromes, Single symptom improvement and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
Shiwei Longdanhua
03
Conditions
chronic bronchitis (CB)
Beyond the preview
Go deeper on ChiCTR2200066665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066665.